Participants will receive a single dose of the tracer, then undergo the scan a short time later. The images are compared with the findings from tissue analysis after surgery or with routine follow‑up scans to confirm whether the cancer has spread. The study follows each participant from the initial scan through surgery and a one‑year follow‑up period to collect the needed information.

The main aim is to see whether this approach can keep the cancer from returning for a longer time, measured as progression-free survival. After the operation, participants are randomly assigned to receive the liver‑directed treatment together with the usual IV chemotherapy, with treatment cycles given every few weeks and regular clinic visits for monitoring.

During the study, patients have routine scans and blood tests to look for any signs of cancer coming back, to check for side effects, and to answer simple questionnaires about overall health and quality of life. Follow‑up continues for several years to record how long patients stay free of disease and to collect safety information.

Participants are randomly assigned to receive either a daily oral pill such as edoxaban or apixaban, an injectable medicine such as dalteparin, tinzaparin, enoxaparin, or rivaroxaban, or a placebo that looks the same but contains no active drug. Over several months, they will have regular check‑ups that may include simple scans of the lungs to confirm whether the clot has changed, and they will complete questionnaires about their daily well‑being. The study does not require any special procedures beyond the usual care for cancer and clot management.

The purpose of the trial is to evaluate the safety and effectiveness of this drug combination. The study begins with a short safety‑checking phase and, if tolerated, moves to a larger phase that looks at how well the treatment shrinks or controls the tumor. Participants receive the infusions every few weeks and undergo regular imaging scans to see changes in tumor size; the study continues until the disease progresses, the participant chooses to stop, or the study ends.

The purpose of the study is to assess the safety and tolerability of mRNA-4359 when used alone and in combination with pembrolizumab. Participants will receive the treatment through injections, and the study will monitor how their bodies respond over time. Some participants will receive a placebo, which is a substance with no active medication, to compare the effects. The study will also involve regular check-ups and tests to ensure the safety of the participants and to gather information on how the treatment affects the cancer.

The study will take place over several years, with participants being closely monitored by healthcare professionals. The goal is to better understand how mRNA-4359 can be used to treat advanced cancers and to determine the best way to use it in combination with existing treatments like pembrolizumab. This research could lead to new options for people with advanced solid tumors, providing hope for more effective treatments in the future.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

Participants receive a combination of medicines: an oral pill called alpelisib (code name BYL719) taken each day, together with two drugs, trastuzumab and pertuzumab, that are given through an intravenous infusion (a drip into a vein). A placebo, which looks like the active pills but contains no medicine, is used for comparison. The purpose of the trial is to find out whether adding alpelisib to the standard HER2‑targeted therapy can keep the cancer from getting worse for a longer time.

The study begins with a safety phase in which a small group receives the drug combination and doctors watch for serious side effects during the first several weeks. If the safety checks are satisfactory, participants move into the main phase where they are randomly assigned, without knowing which group they are in, to receive either the full drug combination or the placebo. They are then followed for several months, with regular check‑ups and scans, to see how long the cancer stays controlled and to monitor any side effects.

The purpose of the study is to understand how safe and tolerable the new treatment is for patients, as well as to see how well it works in reducing the size of the cancer. Participants in the study will receive the investigational treatment, and their response to the treatment will be monitored over time. The study will also look at how long any positive effects of the treatment last.

Throughout the study, researchers will keep track of any side effects experienced by participants and whether these side effects lead to stopping the treatment. The study aims to gather important information that could help in developing new treatment options for people with this type of cancer. The trial is expected to continue until early 2028.

The study will be conducted in two phases. In the first phase, the goal is to determine the safest and most effective dose of the combination of selinexor and gemcitabine. In the second phase, the study will evaluate how well this combination works in preventing the cancer from getting worse over a period of six months. Participants will receive the treatment and be monitored regularly to assess their response to the medication and any side effects they may experience.

Throughout the study, participants will undergo various assessments to monitor their health and the progress of their cancer. These assessments will include regular check-ups and tests to ensure the treatment is working as intended and to manage any potential side effects. The study aims to provide valuable information on the effectiveness and safety of using selinexor and gemcitabine together for treating advanced soft-tissue sarcomas.

The purpose of the study is to see if this treatment can help patients live longer without the cancer coming back. Participants in the study will receive the chemotherapy treatment over a period of 12 months. The study will monitor the patients’ health and check for any signs of the cancer returning. The researchers will also look at how well the treatment works before surgery and how patients respond to the chemotherapy. The study will collect information on any side effects experienced by the participants to ensure the treatment is safe and effective.

Throughout the study, various tests and analyses will be conducted to understand the impact of the treatment on the cancer. This includes looking at specific markers in the cancer cells and analyzing genetic information to see how it might affect the response to the treatment. The study will also involve regular check-ups and assessments to track the overall health and survival of the participants. The goal is to gather valuable information that could lead to better treatment options for patients with this type of cancer in the future.

Participants in the study will be divided into two groups. One group will receive panitumumab first, followed by regorafenib if the disease progresses. The other group will receive the treatments in the reverse order, starting with regorafenib and then switching to panitumumab if needed. The study will help determine which sequence of treatments is more effective for patients with this type of cancer.

The trial will last for a period of time during which participants will receive the treatments and be monitored for their health and response to the medications. The main goal is to see which treatment sequence helps patients live longer. The study will also look at the side effects of the treatments and how well the cancer responds to them. Participants will receive either the study medications or a placebo, depending on the group they are assigned to.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

Participants in the study will receive AL8326 as a second-line treatment, which means it is given after the initial treatment has been completed. The study will explore different doses of the medication to find the best balance between effectiveness and safety. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will last for a period of up to 12 months, during which the health and response of the participants will be closely monitored.

The trial aims to determine the optimal dose of AL8326 that provides the best results for patients with SCLC. This includes looking at how well the cancer responds to the treatment and how long the benefits last. The study will also gather information on how the body processes the medication and any potential side effects. This research is important for improving treatment options for patients with Small Cell Lung Cancer who need further therapy after their initial treatment.

The purpose of the study is to evaluate a new way of monitoring patients using a method called ctDNA-based surveillance. This involves checking for tiny pieces of cancer DNA in the blood, which can indicate if the cancer is coming back. The study will compare this new method with standard monitoring techniques to see if it can help detect relapses earlier and improve survival rates. Participants will undergo regular scans and blood tests over a period of time to monitor their condition.

Throughout the study, researchers will collect information on how well the new monitoring method works, including any side effects from the 68Ga-FAPI-46 PET-CT scans. The study will also look at how the new method compares to existing imaging procedures, such as 18F-FDG PET-CT, in terms of detecting cancer spread. The trial is expected to run until 2028, with the goal of improving early detection and treatment strategies for patients with high-risk triple-negative breast cancer.

The purpose of the study is to understand how aspirin affects the chances of cancer coming back and the overall survival of patients with stage II and III colon cancer. Participants in the study will take either aspirin or a placebo every day for up to five years. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving aspirin and who is receiving the placebo, to ensure unbiased results.

Throughout the study, researchers will monitor the participants’ health to see if the cancer returns and to track their overall survival. The main goal is to see if taking aspirin can help improve survival rates over five years. The study will also look at how long patients remain free from cancer and how long they can continue the treatment without any issues. This research aims to provide valuable insights into the potential benefits of aspirin for patients who have undergone surgery for colon cancer.

The purpose of the study is to see how well the combination treatment works compared to the single medication in preventing the return of melanoma after it has been surgically removed. Participants in the study will be randomly assigned to receive either the combination treatment or the single medication. Some participants may receive a placebo, which is a substance with no active medication. The study will last for up to 12 months, during which time participants will receive regular infusions and be monitored for any changes in their condition.

Throughout the study, researchers will keep track of how long participants remain free from melanoma returning, as well as other important health outcomes. These include how long participants live without the cancer spreading to other parts of the body, overall survival rates, and any side effects experienced. The study will also assess changes in participants’ quality of life and physical functioning. This information will help determine the effectiveness and safety of the combination treatment compared to the single medication.

Table of Contents

• Clinical trial overview
• Who the study is for
• Study design and treatment groups
• What the trial is trying to find out
• Main outcome being measured
• Key points for patients

Clinical trial overview

This study is an interventional trial, which means people are assigned to receive a treatment being tested.^[1] It is testing HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST SEZ6, CONJUGATED TO (2S)-2-(2-BROMOACETAMIDO)-N-[(2S)-1-({3-[(7S)-7-ETHYL-7-HYDROXY-8,11-DIOXO-7,8,11,13-TETRAHYDRO-2H,10H-[1,3]DIOXOLO[4,5-G]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-14-YL]BICYCLO[1.1.1]PENTAN-1-YL}AMINO)-1-OXOPROPAN-2-YL]-3-METHYLBUTANAMIDE in combination with atezolizumab, compared with standard of care as first-line treatment for extensive-stage small cell lung cancer.^[1]

The trial is Phase 2 and has an enrollment target of 180 participants.^[1] Its status is listed as Authorised.^[1]

Who the study is for

The study is for people with previously untreated extensive-stage small cell lung cancer.^[1] “Previously untreated” means the person has not yet had treatment for this cancer.^[1] “Extensive-stage” means the cancer has spread widely.^[1]

Study design and treatment groups

The trial compares two approaches: HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST SEZ6, CONJUGATED TO (2S)-2-(2-BROMOACETAMIDO)-N-[(2S)-1-({3-[(7S)-7-ETHYL-7-HYDROXY-8,11-DIOXO-7,8,11,13-TETRAHYDRO-2H,10H-[1,3]DIOXOLO[4,5-G]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-14-YL]BICYCLO[1.1.1]PENTAN-1-YL}AMINO)-1-OXOPROPAN-2-YL]-3-METHYLBUTANAMIDE plus atezolizumab, and standard of care treatment.^[1] The standard treatment listed in the trial includes carboplatin and etoposide, with atezolizumab also shown in the study treatment list.^[1]

What the trial is trying to find out

The brief summary says the study is designed to evaluate safety and tolerability, meaning how safe the treatment is and how well people can handle it.^[1] It also aims to optimize and select the recommended Phase 3 dose, which is the dose chosen for testing in a larger later study.^[1] A third goal is to evaluate efficacy, meaning whether the treatment helps against the cancer.^[1]

Main outcome being measured

The main outcome is progression-free survival (PFS), measured by investigator assessment using RECIST v1.1.^[1] PFS is the amount of time people live without the cancer getting worse.^[1] RECIST v1.1 is a standard set of rules doctors use to judge tumor changes on scans.^[1]

Key points for patients

• This is a study in small cell lung cancer, not in many different cancer types.^[1]

• The study is for people who have not yet received treatment for this cancer.^[1]

• Researchers are looking at both the study treatment and standard care to see which approach works better.^[1]

• The main focus is on whether the treatment can delay the cancer from getting worse.^[1]

• The trial is still in the research stage, so the results are not yet known.^[1]

Table of Contents

• Trial overview
• Who the trial is for
• What the study measures
• Treatments being compared
• Study design and phase
• What the results mean for patients

Trial overview

This clinical trial is studying AZD0120 in people with relapsed or refractory multiple myeloma.^[1] The trial is designed to see how well AZD0120 works and how safe it is compared with standard therapy.^[1]

Who the trial is for

The trial is for people with relapsed or refractory multiple myeloma.^[1] Relapsed means the cancer came back after treatment, and refractory means the cancer did not respond well to treatment.^[1]

What the study measures

The main outcome is progression-free survival (PFS), which is the time from randomisation until the cancer gets worse or the person dies from any cause, whichever happens first.^[1] The trial also measures the MRD negative complete response rate at 9 months, which means the share of people who have no measurable residual disease and a complete or stringent complete response at that time point.^[1]

Treatments being compared

The study compares AZD0120 with standard therapy options listed as DKd, DPd, PVd, or Kd.^[1] These are treatment combinations used as the control group, so the researchers can see whether AZD0120 gives better results.^[1]

• DKd is one of the standard therapy options named in the trial.^[1]

• DPd is one of the standard therapy options named in the trial.^[1]

• PVd is one of the standard therapy options named in the trial.^[1]

• Kd is one of the standard therapy options named in the trial.^[1]

Study design and phase

This is an interventional study, which means the researchers give treatment and then measure the results.^[1] It is a Phase 3 trial, which is a later-stage study that compares a new treatment with standard care in a larger group of people.^[1] The trial has an enrollment of 508 people and is currently authorised.^[1]

What the results mean for patients

The study is focused on whether AZD0120 can help people stay free from disease worsening for longer than standard treatment.^[1] It also looks for deep responses, meaning the cancer is harder to detect with sensitive tests.^[1] These results help show whether AZD0120 may be a better option for people whose myeloma has returned or is not responding well.^[1]

Table of contents

• Trial overview
• Who can participate
• What is being studied
• What outcomes are measured
• Trial phase and status
• Key patient terms

Trial overview

The available trial is a first-in-human study, which means it is the first time this approach is being tested in people.^[1] It is designed to study the safety and preliminary efficacy of expanded autologous urothelial cells bioprinted during orthotopic neobladder surgery.^[1]

The study is interventional, so the research team gives the study procedure as part of the trial instead of only observing patients.^[1] The planned enrollment is 6 patients.^[1]

Who can participate

The trial is for patients with muscle-invasive bladder cancer (MIBC) who are eligible for neobladder reconstruction after radical cystectomy.^[1] Radical cystectomy means surgery to remove the bladder.^[1]

This means the study is focused on a very specific group of people who are already planned for major bladder surgery and may receive a new bladder, called an orthotopic neobladder.^[1]

What is being studied

The trial is studying AUROCELL-TX, listed in the source as aUroCell-Tx, used with the InvivoLPrint-U bioprinter during neobladder surgery.^[1] A bioprinter is a device that places living cells in a planned shape or structure for medical use.^[1]

The study summary says the goal is to evaluate the safety of the expanded autologous urothelial cells and the bioprinter combination in the surgical setting.^[1] In simple terms, researchers want to see whether this approach can be used safely during surgery and whether there are early signs that it may help.^[1]

What outcomes are measured

The main outcomes focus on safety after surgery.^[1] These include the proportion of patients with a fatal event (death), neobladder rejection, and the need for revision surgery.^[1]

The trial also measures the proportion of patients who are free from the combined endpoint of death, neobladder rejection, and need for revision surgery.^[1] A composite endpoint is one result that combines several important events into a single measure.^[1]

Researchers will also record peri- and post-surgical complications and serious adverse events (SAEs).^[1] These are important because they show what problems happen during surgery and in the recovery period.^[1]

Trial phase and status

This is a Phase 1 trial.^[1] Phase 1 studies are early trials that mainly look at safety and how the study approach performs in a small number of people.^[1]

The study status is Authorised.^[1] That means the trial has been approved to move forward.^[1]

Key patient terms

Autologous means the cells come from the same person who will receive them.^[1] This is important because the trial is using the patient’s own urothelial cells.^[1]

Urothelial cells are cells that line the inside of the urinary tract, including the bladder.^[1] Orthotopic neobladder means a new bladder made during surgery and placed in the usual bladder position.^[1]

Revision surgery means another operation is needed to fix or adjust the first surgery result.^[1] Peri-surgical means around the time of surgery, and post-surgical means after surgery.^[1]

Table of contents

• Trial overview
• Study parts and treatment plan
• Who can join
• What researchers measure
• Trial status and size

Trial overview

AZD0516 is being studied in an interventional clinical trial for adults with metastatic prostate cancer, which means prostate cancer that has spread to other parts of the body.^[1]

The listed trial is a Phase 1/2 study, so it is designed to learn about safety first and then look for early signs that the treatment may help.^[1]

Study parts and treatment plan

The study has several parts: dose escalation in Part A, dose optimisation in Part B, and efficacy expansion in Part C.^[1]

In Part A, researchers are checking safety and trying to find the maximum tolerated dose and/or the recommended dose of AZD0516 when used alone and with anti-cancer agents.^[1]

In Parts B and C, the study looks at early anti-tumour activity, which means whether the treatment shows signs of helping against the cancer.^[1]

AZD0516 is being tested both as monotherapy, meaning by itself, and in combination with other anti-cancer treatments.^[1]

Who can join

The trial is for adults with metastatic prostate cancer.^[1]

This means the study is focused on people whose prostate cancer has already spread, rather than people with early-stage disease.^[1]

What researchers measure

The main safety measures include the number of adverse events, serious adverse events, and adverse events of special interest, as well as dose-limiting toxicities.^[1]

Researchers also check whether people stop AZD0516 because of toxicity, which means harmful side effects that make treatment hard to continue.^[1]

Other safety checks include changes in laboratory tests, vital signs, ECG results, ECOG performance status, and physical examination findings.^[1]

For early efficacy, one key measure is the PSA50 response rate, which means the share of patients whose PSA level drops by at least 50%.^[1]

Trial status and size

The listed trial is currently Authorised.^[1]

The planned enrollment is 401 participants, which shows that this is a relatively large early-phase study.^[1]

Table of Contents

• Trial overview
• Who can join the study
• What is being measured
• Study parts and treatment plan
• Trial phase and study size

Trial overview

This authorised interventional study is testing AZD3632 in adults with relapsed or refractory acute leukaemia or myelodysplastic syndromes with HOX overexpression genotypes.^[1] The trial is designed to learn about safety, tolerability, early signs of benefit, and how the treatment moves through the body over time.^[1]

The study is in Phase 1/2, which means it is an early trial that first focuses on safety and dose, while also starting to look at whether the treatment may help people with these blood cancers.^[1]

Who can join the study

The target population includes adults with relapsed disease, meaning the cancer came back after treatment, or refractory disease, meaning the cancer did not respond well to treatment.^[1] The study also includes people with myelodysplastic syndromes that have HOX overexpression genotypes, which means a specific gene pattern is present.^[1]

These details show that the trial is aimed at people with advanced haematologic malignancies, which is a medical term for cancers of the blood and bone marrow.^[1]

What is being measured

The main safety goal in Module 1 is to measure the incidence of dose-limiting toxicity during the dose-limiting toxicity evaluation period.^[1] This means the researchers are checking whether side effects become serious enough to limit treatment.^[1]

Both Module 1 and Module 2 measure the frequency of dose modifications, delays, and discontinuations because of adverse events.^[1] They also measure treatment-emergent adverse events, treatment-related adverse events, and serious adverse events.^[1]

The study also tracks changes from baseline in laboratory tests, 12-lead ECGs, performance status, physical examination findings, and vital signs.^[1] In simple terms, the researchers are watching blood tests, heart tracing tests, general daily functioning, body checks, and basic body measurements to see how participants are doing during the trial.^[1]

Study parts and treatment plan

Module 1 studies AZD3632 monotherapy, which means AZD3632 is given by itself.^[1] In this part, the study aims to assess safety and tolerability and to identify the optimal biologic dose.^[1]

Module 2 studies AZD3632 when it is co-administered with posaconazole, meaning the two treatments are given together.^[1] In this part, the main safety goal is to assess safety and tolerability of the combination.^[1]

The trial title also states that researchers want to learn how AZD3632 moves throughout the body over time, which is a way of studying how the treatment behaves in the body during the trial.^[1]

Trial phase and study size

This is a single interventional study with a planned enrollment of 60 participants.^[1] The authorised status shows that the study has been approved to proceed.^[1]

Because the study is early phase, it is mainly designed to gather safety information and help researchers choose the best dose for future research.^[1] It also begins to collect early signs of whether AZD3632 may help people with these specific blood cancers.^[1]

Table of Contents

• What is tifcemalimab (JS004)?
• What cancers are being studied?
• How tifcemalimab is given in these trials
• Phase 3 consolidation trial in limited-stage SCLC (NCT06095583)
• Exploratory first-line trial in extensive-stage SCLC (NCT06732258)
• What outcomes (endpoints) the trials measure
• How safety is monitored in these trials

What is tifcemalimab (JS004)?

Tifcemalimab (also described as JS004) is a monoclonal antibody drug designed to target BTLA (B and T lymphocyte attenuator), which is a molecule involved in reducing immune activity (sometimes explained as an immune “brake”). In the provided trials, it is being studied as an immunotherapy approach for small cell lung cancer, often paired with another immunotherapy drug, toripalimab.^[1][2]

Toripalimab is also a monoclonal antibody, but it targets PD-1 (programmed death protein-1), another immune “brake.” The trials are exploring whether blocking these immune checkpoints (BTLA and PD-1) can improve cancer control in small cell lung cancer when used alone or together, depending on the study design.^[1]

What cancers are being studied?

The provided clinical trial records study tifcemalimab in Small Cell Lung Cancer (SCLC), which is a fast-growing type of lung cancer. Two stages/settings are included in these trials: Limited-stage Small Cell Lung Cancer (LS-SCLC) and Extensive-stage Small-cell Lung Cancer (ES-SCLC).^[1][2]

• LS-SCLC: In one phase 3 trial, patients have limited-stage disease and have already received chemoradiotherapy (CRT) (chemotherapy plus radiation). Importantly, the study focuses on patients who have no disease progression after CRT, and then tests immunotherapy as consolidation therapy (extra treatment after the first main treatment to help keep cancer controlled).^[1]
• ES-SCLC: In one exploratory trial, tifcemalimab is tested in the first-line setting (the first treatment given) for extensive-stage disease, together with chemotherapy, toripalimab, and low-dose radiotherapy.^[2]

How tifcemalimab is given in these trials

In the provided studies, tifcemalimab is given as an intravenous infusion (IV), meaning the medicine is delivered into a vein. The dosing schedule in both trials is every 3 weeks (often written as q3w).^[1][2]

• In the phase 3 LS-SCLC consolidation trial, tifcemalimab is listed as 200 mg IV once every 3 weeks, and toripalimab is 240 mg IV once every 3 weeks in the combination arm.^[1]
• In the ES-SCLC exploratory study, tifcemalimab is tested at 100 mg or 200 mg every 3 weeks together with toripalimab 240 mg every 3 weeks, and treatment continues until disease progression (cancer clearly worsens) or intolerable toxicity (side effects are too severe to continue).^[2]

Phase 3 consolidation trial in limited-stage SCLC (NCT06095583)

This study is a Phase 3, randomized, double-blind, placebo-controlled, multi-regional clinical trial. These terms mean: Phase 3 is a large later-stage trial, randomized means assigned by chance, double-blind means the treatment is masked (hidden) to reduce bias, placebo-controlled means some participants receive inactive infusions for comparison, and multi-regional means it is run across multiple regions.^[1]

The trial tests consolidation therapy in patients with LS-SCLC who do not have disease progression after chemoradiotherapy (CRT). Consolidation therapy here means additional treatment after CRT to try to keep the cancer controlled for longer.^[1]

• Arm A (experimental): tifcemalimab 200 mg IV + toripalimab 240 mg IV every 3 weeks.^[1]
• Arm B (experimental): toripalimab 240 mg IV every 3 weeks + placebo for tifcemalimab.^[1]
• Arm C (placebo comparator): placebo for both drugs (placebos for tifcemalimab and toripalimab) every 3 weeks.^[1]

The record also states that tifcemalimab is a monoclonal antibody against BTLA and toripalimab is a monoclonal antibody against PD-1, and that this combination regimen is investigational (not approved as standard treatment) in limited-stage SCLC in any country according to the trial description.^[1]

Exploratory first-line trial in extensive-stage SCLC (NCT06732258)

This study is a single-center, single-arm, exploratory clinical study in ES-SCLC (extensive-stage disease). Single-arm means everyone receives the same treatment (there is no placebo/control group in this study). The aim is to evaluate tolerability and safety and determine the RP2D (recommended Phase 2 dose).^[2]

The trial uses a 3 + 3 dose escalation design, which is a method used in early trials to find a dose that people can tolerate. A key safety window is the first 21 days after the first dose, when dose-limiting toxicities (DLTs) are monitored. DLTs are side effects serious enough to limit how much drug can be safely given.^[2]

The treatment approach combines four components: low-dose radiotherapy, standard chemotherapy drugs, toripalimab, and tifcemalimab. This is designed to study safety and early signs of cancer response in the first-line setting for ES-SCLC.^[2]

• Low-dose radiotherapy: total dose 15 Gy delivered in 5 fractions (15 Gy/5F), starting on Cycle 1 Day 1. Gy is a unit of radiation dose, and fractions are separate treatment sessions.^[2]
• Chemotherapy: cisplatin 75 mg/m² every 3 weeks or carboplatin at AUC = 5 every 3 weeks, plus etoposide 100 mg/m² on days 1, 2, and 3 every 3 weeks for 4–6 cycles. These are standard chemotherapy drugs used to kill or slow cancer cell growth.^[2]
• Toripalimab: 240 mg every 3 weeks until disease progression or intolerable toxicity.^[2]
• Tifcemalimab: 100 mg or 200 mg every 3 weeks until disease progression or intolerable toxicity (the dose levels support the dose-escalation goal and RP2D selection).^[2]

What outcomes (endpoints) the trials measure

Clinical trials use outcomes (also called endpoints) to measure whether a treatment is helping and how safe it is. In these tifcemalimab trials, outcomes include survival, time without cancer worsening, and tumor response categories.^[1][2]

• Overall survival (OS): how long participants live. In the phase 3 LS-SCLC trial, OS is a primary outcome used to compare Arm A versus placebo and Arm B versus placebo.^[1]
• Progression-free survival (PFS): how long participants live without the cancer getting worse. In the LS-SCLC trial, PFS is assessed by a Blinded Independent Review Committee (BIRC) to reduce bias, and there are also investigator-assessed PFS secondary outcomes. In the ES-SCLC trial, PFS is also measured as time from enrollment to progression or death.^[1][2]
• Objective response rate (ORR): the proportion of participants who have a measurable tumor shrinkage, defined as complete response (CR) or partial response (PR). ORR is included as a secondary outcome in both trials (listed in LS-SCLC and defined clearly in ES-SCLC).^[1][2]
• Disease control rate (DCR): the proportion of participants who have CR, PR, or stable disease (SD), meaning the cancer shrinks or does not grow for a time. DCR is listed as a secondary outcome in the LS-SCLC trial and defined in the ES-SCLC trial.^[1][2]
• Duration of response (DoR/DOR): how long a response lasts from first documented response until progression or death. DoR is included in both trials (and defined in the ES-SCLC study).^[1][2]
• In the LS-SCLC phase 3 trial, 1-year and 2-year OS rates are also included as secondary outcomes for both the combination comparison and the toripalimab-only comparison versus placebo.^[1]

How safety is monitored in these trials

Safety monitoring in these studies focuses on side effects (called adverse events) and laboratory test changes, and in the ES-SCLC exploratory study it also focuses on early serious side effects called dose-limiting toxicities (DLTs).^[1][2]

• In the phase 3 LS-SCLC consolidation trial, safety is evaluated by the incidence (percentage of participants affected) of treatment-related adverse events graded using CTCAE v5.0 (a standard system to rate side effect severity) and by abnormal laboratory parameters, comparing combination therapy versus placebo and toripalimab versus placebo.^[1]
• In the ES-SCLC exploratory study, the primary safety outcome is the number of participants with DLTs during the first 21 days after the first dose. This period helps researchers decide which dose levels are tolerable and supports choosing the RP2D for future studies.^[2]

Table of Contents

• What are TIL cells?
• Which clinical trials and cancers are being studied?
• How TIL therapy is given in these studies
• What outcomes are measured (safety and effectiveness)
• Who may join these trials (common inclusion and exclusion themes)
• Immune tests and biomarkers studied

What are TIL cells?

TIL cells stands for tumor-infiltrating lymphocytes. These are immune cells, mainly T-cells, that are already inside a person’s tumor. The idea behind TIL therapy is to use these tumor-fighting cells as a treatment.

In the trials provided, TIL cells are described as a cell therapy product given by intravenous infusion (through a vein). One investigational version is called Meta10-TIL, described as “metabolically armed” TIL therapy for people with advanced solid tumors.

^[1]

Which clinical trials and cancers are being studied?

The provided trial data includes TIL-based approaches in several cancer settings:

• Advanced solid tumors: An open-label study evaluates the safety and signs of benefit of Meta10-TIL therapy in advanced solid tumors.

• Metastatic melanoma: A phase I/II, single-center study (ACTME) evaluates TIL therapy together with nivolumab, and later the combination of TIL plus low-dose PEG-IFNα plus nivolumab, for progressive unresectable stage III or stage IV melanoma.

• Ovarian carcinoma: A phase I/II trial (OVACURE-2) studies adoptive T cell therapy (using TIL cells) plus low-dose IL-2 as a first-line neoadjuvant strategy in stage III/IV epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer.

^[1][2][3]

How TIL therapy is given in these studies

Across the trials, the TIL product is given as an infusion into a vein.

• Meta10-TIL for advanced solid tumors: Participants receive nonmyeloablative lymphodepletion chemotherapy (a pre-treatment that reduces immune cells without fully wiping out bone marrow function) with cyclophosphamide and fludarabine, followed by Meta10-TIL infusion on day 0.

• ACTME in metastatic melanoma: The study evaluates safety and toxicity of TIL and nivolumab first, and later the combination of TIL, PEG‑IFNα, and nivolumab.

• OVACURE-2 in ovarian cancer: The study evaluates TIL-based adoptive T cell therapy plus low-dose IL-2, and aims to determine dosing for phase II based on dose-limiting toxicities (DLTs).

^[1][2][3]

What outcomes are measured (safety and effectiveness)

Safety outcomes

A central goal in these studies is to understand side effects. Trials measure adverse events (AEs) and grade them with CTCAE (a standard scale for severity).

• In the Meta10-TIL advanced solid tumor study, the primary outcome is adverse events graded by NCI CTCAE v5.0 over 1 year after infusion.

• In ACTME metastatic melanoma, safety and toxicity are evaluated using CTCAE 4.0, and certain grade 3 toxicities and serious adverse events may be considered acceptable if they do not lead to stopping treatment.

• In OVACURE-2 ovarian cancer, toxicity related to TIL plus low-dose IL-2 is assessed using NCI CTCAE v5.0, with a focus on grade greater than III and identifying DLTs to help choose a recommended dose for phase II.

^[1][2][3]

Effectiveness outcomes

These trials also look for signs the treatment may control cancer. Common measures include:

• Objective response rate (ORR): The percent of patients with a confirmed partial response (PR) or complete response (CR), often measured with RECIST v1.1.

• Duration of response (DOR): How long a PR or CR lasts before the cancer grows or the patient dies.

• Progression-free survival (PFS): Time until the cancer progresses or death occurs.

• Overall survival (OS): Time from a defined study point (for example, infusion date) to death.

• Disease control rate (DCR): Percent of patients with CR, PR, or stable disease (SD).

In the ACTME melanoma study, disease control is assessed with imaging such as CT and/or MRI using RECIST 1.1 and also immune-related response criteria (irRC), which are sometimes used in immunotherapy research to better capture immune-related patterns of tumor change.

^[1][2]

Who may join these trials (common inclusion and exclusion themes)

Each study has its own detailed rules. From the provided trial text, common themes include confirming the cancer type and stage, showing the cancer can be measured (or tracked) in standard ways, and making sure general health is strong enough for intensive immunotherapy approaches.

Examples of inclusion requirements described in the provided trials

• Confirmed diagnosis and stage (for example, metastatic melanoma stage III unresectable or stage IV; or epithelial high-grade ovarian/fallopian tube/primary peritoneal cancer stage III/IV).

• Measurable disease using RECIST v1.1 (some ovarian cancer participants may also qualify via elevated CA125 criteria as described).

• Functional status requirements such as WHO performance status ≤ 1 or ECOG performance status 0–1, meaning the person is fairly active and able to care for themselves.

• Laboratory values in acceptable ranges (blood counts and organ function measures), and negative viral testing for infections such as HIV, hepatitis B, and hepatitis C as specified.

Examples of exclusion considerations described in the provided trials

• Pregnancy or breastfeeding.

• Some forms of serious heart disease, such as NYHA Class III or IV.

• Active serious infections requiring antibiotics.

• Active immunodeficiency or autoimmune disease requiring immune-suppressing drugs (with vitiligo specifically noted as not excluding participation in these trials).

• Brain metastases limitations differ by study: the melanoma trial allows brain metastases only if neurologically stable for at least 2 months and without dexamethasone; the ovarian trial excludes brain metastases.

^[2][3]

Immune tests and biomarkers studied

Beyond tumor measurements and side effects, some trials include detailed immune research to understand why some patients respond better than others.

• The metastatic melanoma ACTME trial includes goals such as building a possible biomarker profile, comparing immune features in patients with and without response, and studying the infused T cell product using immunomonitoring. It also describes evaluating immune characteristics in PBMCs (blood immune cells) and exploring differences between CD8-rich and CD8-poor metastases, including using CD8-immunoPET/CT methods as described in the trial record.

• The ovarian cancer OVACURE-2 trial lists secondary objectives including immune monitoring with TCR clonotypes and tracking immune cell subsets such as CD8/CD4 and other immune cell categories named in the protocol summary.

• The Meta10-TIL advanced solid tumor trial includes plans to characterize pharmacokinetic (PK) and pharmacodynamic (PD) profiles, which broadly means tracking the therapy in the body over time and its biological effects.

^[1][2][3]

Table of Contents

• What is Timolol Maleate?
• Uses of Timolol Maleate
• How Timolol Maleate Works
• Forms and Administration
• Effectiveness
• Side Effects and Safety
• Ongoing Research

What is Timolol Maleate?

Timolol Maleate is a medication that belongs to a class of drugs called beta-blockers. It’s primarily used to treat eye conditions, but researchers are also exploring its potential in treating other medical issues. Timolol Maleate is known by several other names, including Timoptic, Timolol, and simply Timolol maleate^[1].

Uses of Timolol Maleate

Timolol Maleate is used to treat several conditions:

• Glaucoma: It’s primarily used to treat open-angle glaucoma, a condition where pressure inside the eye is too high, which can damage the optic nerve and lead to vision loss^[2].
• Ocular Hypertension: This is a condition where the pressure inside the eye is higher than normal, but hasn’t yet caused optic nerve damage^[2].
• Infantile Hemangioma: Some studies are exploring the use of Timolol Maleate to treat infantile hemangioma, which are benign (non-cancerous) growths of blood vessels that appear as red marks on infants’ skin^[3].
• Chronic Wounds: Researchers are investigating whether Timolol Maleate can help heal chronic wounds, such as diabetic foot ulcers or pressure sores^[4].

How Timolol Maleate Works

Timolol Maleate works by blocking certain receptors in the body called beta receptors. In the eye, this action helps to reduce the production of fluid (aqueous humor) inside the eye, which in turn lowers the pressure inside the eye. This is particularly important in treating glaucoma and ocular hypertension^[5].

Forms and Administration

Timolol Maleate comes in several forms:

• Eye Drops: This is the most common form for treating eye conditions. It’s usually available as a 0.5% solution^[1].
• Gel-Forming Solution: This form turns into a gel when it contacts the eye, which may help the medication stay in the eye longer^[6].
• Topical Gel: For treating conditions like infantile hemangioma, Timolol Maleate may be applied as a gel directly to the skin^[3].

The frequency of administration depends on the condition being treated and the form of the medication. For eye conditions, it’s typically used once or twice daily^[2].

Effectiveness

Timolol Maleate has been shown to be effective in lowering intraocular pressure (pressure inside the eye) in patients with glaucoma or ocular hypertension. In one study, patients using Timolol Maleate experienced a significant reduction in eye pressure after 8 weeks of treatment^[7].

For infantile hemangioma, early research suggests that Timolol Maleate may help reduce the size and color of these skin growths, although more studies are needed to confirm its effectiveness^[3].

Side Effects and Safety

Like all medications, Timolol Maleate can cause side effects. When used as eye drops, some common side effects may include:

• Stinging or burning sensation in the eyes
• Blurred vision
• Eye redness
• Tearing
• Light sensitivity^[2]

When absorbed into the bloodstream, Timolol Maleate can potentially affect other parts of the body. Researchers are studying how much of the drug enters the bloodstream when applied to the eye or skin, to ensure it’s safe for long-term use^[4].

Ongoing Research

Scientists continue to study Timolol Maleate to understand its full potential and ensure its safety. Some areas of ongoing research include:

• Comparing different formulations of Timolol Maleate to see which is most comfortable for patients^[1].
• Investigating its use in treating infantile hemangioma, including determining the optimal dosage and application method^[3].
• Exploring its potential in healing chronic wounds^[4].
• Studying how it interacts with other medications, such as antidepressants^[8].

These studies aim to improve our understanding of Timolol Maleate and potentially expand its uses in treating various medical conditions.

Table of Contents

• What is Toripalimab?
• How Does Toripalimab Work?
• Cancers Treated with Toripalimab
• Toripalimab in Clinical Trials
• Administration and Dosage
• Potential Side Effects
• Future Prospects

What is Toripalimab?

Toripalimab is a type of cancer drug known as an immunotherapy. It’s also referred to by other names such as JS001, TAB001, or TORIPALIMAB INJECTION (JS001)^[1]. This medication is designed to help your body’s immune system fight cancer cells more effectively.

How Does Toripalimab Work?

Toripalimab belongs to a class of drugs called PD-1 inhibitors. PD-1 is a protein on immune cells that acts like a “brake” to prevent them from attacking other cells. Some cancer cells can use this brake to avoid being destroyed by the immune system. Toripalimab works by blocking this brake, allowing the immune system to recognize and attack cancer cells more effectively^[1].

Cancers Treated with Toripalimab

Toripalimab is being studied for the treatment of several types of cancer, including:

• Non-small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer^[2][1].
• Small Cell Lung Cancer (SCLC): A less common but more aggressive form of lung cancer^[3].
• Nasopharyngeal Carcinoma (NPC): A type of cancer that starts in the nasopharynx, the upper part of the throat behind the nose^[4].
• Mucosal Melanoma: A rare type of melanoma that occurs on mucous membranes^[5].
• Breast Cancer: Specifically, HR-positive, HER2-negative breast cancer^[6].
• Laryngeal and Hypopharyngeal Cancer: Cancers that affect the voice box (larynx) and the lower part of the throat (hypopharynx)^[7].

Toripalimab in Clinical Trials

Toripalimab is currently being studied in several clinical trials to determine its effectiveness in treating various cancers. These trials are investigating:

• Toripalimab combined with chemotherapy for advanced NSCLC^[2][1].
• Toripalimab with chemotherapy for extensive-stage small cell lung cancer^[3].
• Toripalimab combined with other targeted therapies, such as axitinib for mucosal melanoma^[5].
• Toripalimab with radiotherapy and chemotherapy for nasopharyngeal carcinoma^[4].
• Toripalimab in combination with stereotactic body radiation therapy (SBRT) for NSCLC^[8].

Administration and Dosage

Toripalimab is typically administered as an intravenous (IV) infusion. The common dosage is 240mg every 3 weeks (Q3W)^[2][1]. However, the exact dosage and schedule may vary depending on the specific cancer type and treatment plan. In some trials, it’s given for up to 2 years or until disease progression or intolerable side effects occur^[3].

Potential Side Effects

As with any medication, Toripalimab can cause side effects. These are carefully monitored in clinical trials. Common side effects of immunotherapy drugs like Toripalimab may include fatigue, skin rashes, and diarrhea. More serious side effects can occur but are less common. It’s important to discuss potential side effects with your healthcare provider^[2][1].

Future Prospects

Researchers are exploring new ways to use Toripalimab, including:

• As a maintenance therapy after initial treatment for small cell lung cancer^[9].
• In combination with radiation therapy for various cancers^[8][7].
• As part of neoadjuvant therapy (treatment given before surgery) for breast cancer^[6].

These ongoing studies aim to determine the most effective ways to use Toripalimab and identify which patients are most likely to benefit from this treatment.

Table of Contents

• What is Taladegib?
• How Taladegib Works
• Conditions Treated with Taladegib
• Dosage and Administration
• Clinical Studies of Taladegib
• Potential Side Effects
• Drug Interactions
• Ongoing Research and Future Directions

What is Taladegib?

Taladegib (also known as LY2940680 or ENV-101) is an investigational anti-cancer medication that belongs to a class of drugs called Hedgehog pathway inhibitors ^[1]. It is being studied for the treatment of various types of cancer and other conditions such as idiopathic pulmonary fibrosis. Taladegib is not yet approved by regulatory agencies for regular clinical use but is being evaluated in multiple clinical trials to assess its safety and effectiveness.

Taladegib is administered orally in the form of tablets or capsules, which makes it convenient for patients as it doesn’t require hospital visits for intravenous administration ^[2]. The medication is currently only available to patients participating in clinical trials.

How Taladegib Works

Taladegib works by targeting and inhibiting a specific cellular pathway called the Hedgehog (Hh) signaling pathway ^[3]. This pathway plays an important role in embryonic development but can become abnormally activated in certain cancers, contributing to tumor growth.

More specifically, taladegib is a potent inhibitor of a protein called Smoothened (Smo), which is a key component of the Hedgehog pathway. By blocking Smoothened, taladegib prevents the activation of Gli1, a transcription factor that, when activated, turns on genes involved in cell growth and survival ^[4]. Scientists can measure the level of Gli1 inhibition in skin biopsies to determine if taladegib is effectively blocking the Hedgehog pathway in patients.

In certain cancers, especially those with mutations in a gene called PTCH1 (Patched-1), the Hedgehog pathway becomes continuously activated. PTCH1 normally functions as a negative regulator of the pathway, and when it has loss-of-function mutations, the pathway becomes overactive, potentially contributing to cancer development ^[5]. Taladegib may be particularly effective in cancers with these specific genetic alterations.

Conditions Treated with Taladegib

Based on clinical trials data, taladegib is being investigated for several medical conditions:

Cancer Types

• Advanced Solid Tumors: Taladegib is being studied in patients with various types of advanced solid tumors, particularly those with specific genetic mutations in the PTCH1 gene ^[5].
• Basal Cell Carcinoma (BCC): This is a type of skin cancer where the Hedgehog pathway is often abnormally activated ^[1].
• Medulloblastoma: A type of brain cancer that occurs mainly in children and sometimes involves Hedgehog pathway activation ^[6].
• Rhabdomyosarcoma: A type of cancer that develops from skeletal muscle cells, most common in children ^[6].
• Small Cell Lung Cancer: Taladegib has been studied in combination with chemotherapy drugs (carboplatin and etoposide) for this aggressive form of lung cancer ^[7].
• Esophageal and Gastroesophageal Junction Adenocarcinoma: Taladegib is being investigated in combination with chemotherapy and radiation therapy for these cancers ^[8].

Non-Cancer Conditions

• Idiopathic Pulmonary Fibrosis (IPF): This is a chronic, progressive lung disease characterized by scarring of lung tissue. Taladegib is being evaluated for its potential to help patients with IPF ^[9].

Dosage and Administration

As taladegib is still in clinical trials, the optimal dosage has not been definitively established. However, from the clinical trials data, several dosage regimens have been studied:

• For advanced solid tumors: Doses ranging from 50 mg to 600 mg once daily have been studied, with 200 mg and 300 mg once daily being common doses in recent trials ^[1][5].
• For idiopathic pulmonary fibrosis: A dose of 200 mg once daily has been studied ^[9].
• For pediatric cancers: Dosages based on body surface area have been used, ranging from 23 mg/m² to 370 mg/m² once daily ^[6].

Taladegib is taken orally, typically once daily, with treatment cycles usually lasting 28 days. In some clinical trials, taladegib is administered in combination with other cancer treatments such as chemotherapy or radiation therapy ^[8].

Clinical Studies of Taladegib

Taladegib has been evaluated in multiple clinical trials to assess its safety, effectiveness, and proper dosing:

Phase 1 Studies

Initial studies focused on determining the safety, tolerability, and proper dosage of taladegib in patients with advanced cancers. These studies found that taladegib could be administered at doses up to 600 mg daily, with the most common side effects being manageable ^[1].

A study in Japanese patients with advanced solid tumors evaluated doses of 100 mg, 200 mg, and 400 mg daily and found that taladegib was generally well-tolerated in this population ^[10].

Another study investigated how taladegib is processed by the body (pharmacokinetics) in healthy volunteers, finding that most of the drug is eliminated through feces ^[11].

Phase 2 Studies

More recent studies have focused on specific patient populations:

• A study is evaluating taladegib at doses of 200 mg and 300 mg once daily in patients with advanced solid tumors that have specific mutations in the PTCH1 gene ^[5].
• Another study is assessing taladegib at a dose of 200 mg once daily in patients with idiopathic pulmonary fibrosis ^[9].
• Taladegib is also being studied in combination with other cancer treatments, such as chemotherapy and radiation therapy, for esophageal and gastroesophageal junction cancers ^[8].

Pediatric Studies

A study specifically focused on children with medulloblastoma or rhabdomyosarcoma that has returned or doesn’t respond to initial treatment is evaluating taladegib at various dosages based on body surface area ^[6].

Potential Side Effects

While taladegib is still being studied and the full profile of side effects is not completely characterized, some potential side effects have been observed in clinical trials:

• Hair loss (alopecia): This is a common side effect of Hedgehog pathway inhibitors ^[1].
• Fatigue: Feeling tired or exhausted is commonly reported ^[1].
• Gastrointestinal symptoms: These may include nausea, vomiting, constipation, or diarrhea ^[7].
• Decreased appetite: Some patients experience reduced desire to eat ^[7].
• Liver enzyme elevations: Temporary increases in liver enzymes have been observed in some patients ^[7].
• Blood count changes: These may include decreases in certain types of blood cells, which could potentially increase the risk of infection, bleeding, or fatigue ^[7].

The severity and frequency of these side effects may depend on the dose of taladegib, whether it’s used alone or in combination with other treatments, and individual patient factors ^[9].

Drug Interactions

Limited information is available about potential drug interactions with taladegib as it is still in clinical development. However, some studies have specifically examined potential interactions:

• A study is investigating the potential interaction between taladegib and nintedanib (a medication used to treat idiopathic pulmonary fibrosis) ^[12].
• Another study evaluated the effects of food and a proton pump inhibitor (a type of medication that reduces stomach acid) on how taladegib is absorbed by the body ^[13].
• Taladegib has also been studied in combination with other cancer drugs, including LY3039478 (a Notch inhibitor), suggesting these medications can be used together ^[14].

As with any medication, it’s important for patients in clinical trials to inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential harmful interactions.

Ongoing Research and Future Directions

Research on taladegib continues to evolve, with several ongoing clinical trials exploring its potential in different conditions and in combination with other treatments:

• A Phase 2 study is evaluating taladegib in patients with advanced solid tumors that have specific mutations in the PTCH1 gene, which may help identify which patients are most likely to benefit from this treatment ^[5].
• Taladegib is being investigated for idiopathic pulmonary fibrosis, which represents a potential expansion beyond cancer treatment ^[9].
• Studies are exploring taladegib in combination with chemotherapy and radiation therapy for various cancers, which may enhance its effectiveness ^[8].
• Research is ongoing to better understand how taladegib interacts with other medications, which will help guide its safe use if it receives regulatory approval ^[12].

The results of these ongoing studies will provide more information about the safety and effectiveness of taladegib and help determine which patients are most likely to benefit from this treatment.

If you are interested in learning more about taladegib or are considering participating in a clinical trial, it’s important to discuss this with your healthcare provider, who can provide personalized information based on your specific medical condition and circumstances.

Table of Contents

• What is Talazoparib?
• How Talazoparib Works
• Conditions Treated with Talazoparib
• How Talazoparib is Administered
• Efficacy of Talazoparib
• Side Effects and Safety Considerations
• Use in Special Populations
• Ongoing Research and Future Directions

What is Talazoparib?

Talazoparib is a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as PARP inhibitors, which work by interfering with cancer cells’ ability to repair their DNA, ultimately leading to their death. Talazoparib is also known by other names, including MDV3800 and BMN673^[1][2].

This drug is primarily used in patients with advanced solid tumors, particularly in those with specific genetic mutations that make their cancer cells more susceptible to PARP inhibition^[3].

How Talazoparib Works

Talazoparib works by inhibiting an enzyme called poly (ADP-ribose) polymerase (PARP). PARP is involved in repairing damaged DNA in cells. By blocking this enzyme, talazoparib prevents cancer cells from repairing their DNA, which leads to the accumulation of DNA damage and eventually causes the cancer cells to die^[4].

This mechanism is particularly effective in cancer cells with mutations in genes like BRCA1 or BRCA2, which are also involved in DNA repair. When both PARP and these genes are not functioning, it becomes very difficult for cancer cells to survive, a concept known as “synthetic lethality”^[5].

Conditions Treated with Talazoparib

Talazoparib is used to treat several types of advanced solid tumors, including:

• Breast cancer: Particularly in patients with HER2-negative breast cancer and mutations in the BRCA1 or BRCA2 genes^[5]
• Ovarian cancer: Including fallopian tube and primary peritoneal cancers^[6]
• Prostate cancer^[7]
• Non-small cell lung cancer (NSCLC)^[7]
• Pancreatic cancer^[7]
• Colorectal cancer^[7]

It’s important to note that talazoparib is often used in patients whose cancer has advanced or spread to other parts of the body (metastasized) and who have specific genetic mutations that make their cancer more likely to respond to this treatment^[3].

How Talazoparib is Administered

Talazoparib is taken orally, usually once daily. The typical dose is 1 mg per day, but this can vary depending on the patient’s condition and response to treatment^[3]. It’s important to take talazoparib exactly as prescribed by your doctor.

The medication can be taken with or without food^[4]. Each treatment cycle typically lasts 28 days, and treatment continues until the disease progresses or unacceptable side effects occur^[3].

Efficacy of Talazoparib

Clinical trials have shown promising results for talazoparib in treating various types of cancer:

• In patients with advanced breast cancer and BRCA mutations, talazoparib has demonstrated significant tumor shrinkage and improved progression-free survival^[5].
• Studies have shown that a significant percentage of patients achieve an objective response (meaning their tumors shrink or disappear) when treated with talazoparib^[4].
• The drug has also shown potential in treating other types of solid tumors, especially in patients with specific genetic mutations^[3].

It’s important to note that the effectiveness of talazoparib can vary depending on the individual patient and the specific characteristics of their cancer.

Side Effects and Safety Considerations

Like all medications, talazoparib can cause side effects. Some of the most common side effects include:

• Fatigue: Feeling very tired or weak
• Anemia: Low red blood cell count, which can cause tiredness and shortness of breath
• Nausea and vomiting
• Decreased appetite
• Diarrhea
• Headache
• Low white blood cell count: This can increase the risk of infections
• Low platelet count: This can increase the risk of bleeding or bruising

More serious side effects, although less common, can include severe bone marrow problems, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)^[8].

It’s crucial to report any side effects to your healthcare provider. They may adjust your dose or provide treatments to manage side effects^[4].

Use in Special Populations

Research has been conducted to understand how talazoparib affects patients with various health conditions:

• Patients with kidney problems: Studies have shown that talazoparib can be used in patients with varying degrees of kidney function, but dose adjustments may be necessary^[1].
• Patients with liver problems: Similar studies have been conducted in patients with liver impairment to determine appropriate dosing^[2].

Always inform your doctor about any existing health conditions you have, as this may affect how talazoparib is prescribed or monitored.

Ongoing Research and Future Directions

Researchers continue to study talazoparib to understand its full potential in cancer treatment. Some areas of ongoing research include:

• Using talazoparib in combination with other cancer treatments to potentially enhance its effectiveness^[4].
• Exploring its use in earlier stages of cancer or as a preventive treatment in high-risk individuals^[5].
• Investigating its effectiveness in other types of cancers or in patients with different genetic profiles^[3].

As research progresses, our understanding of how best to use talazoparib in cancer treatment continues to evolve. Your oncologist can provide the most up-to-date information about how this medication might fit into your specific treatment plan.

Table of Contents

• What is Tagraxofusp?
• How Does Tagraxofusp Work?
• What Conditions Does Tagraxofusp Treat?
• How is Tagraxofusp Administered?
• Current Clinical Use and Research
• Tagraxofusp in Combination Therapies
• Potential Side Effects
• Ongoing Research and Future Applications
• Tagraxofusp in Pediatric Patients

What is Tagraxofusp?

Tagraxofusp (also known by the brand name Elzonris, or formerly SL-401) is a targeted therapy used in the treatment of certain blood cancers^[1]. It belongs to a class of medications called CD123-directed cytotoxins, which means it specifically targets a protein called CD123 that is found on the surface of certain cancer cells^[2].

Tagraxofusp is a protein-drug conjugate that consists of two parts: a targeting portion (interleukin-3) that binds to CD123, and a toxic portion (truncated diphtheria toxin) that kills the cells once the drug is taken up^[3]. The U.S. Food and Drug Administration (FDA) has approved tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in both adult and pediatric patients^[4].

How Does Tagraxofusp Work?

Tagraxofusp works through a targeted approach to kill cancer cells. Here’s how it works:

1. The medication targets a specific protein called CD123 (also known as the interleukin-3 receptor alpha chain) that is found in high amounts on certain cancer cells^[5].
2. Once tagraxofusp binds to CD123, the cancer cell absorbs the drug^[5].
3. Once inside the cell, the diphtheria toxin portion of tagraxofusp is released, which prevents the cell from making new proteins^[3].
4. Without the ability to make new proteins, the cancer cell dies^[3].

What makes tagraxofusp different from conventional chemotherapy is that it directly targets CD123, which is present on tumor cells but is expressed at lower levels or absent on normal hematopoietic stem cells (the cells in your bone marrow that give rise to all blood cells)^[12]. Additionally, tagraxofusp’s killing mechanism is not dependent on cell division, making it effective against both highly proliferative tumor cells and quiescent (inactive) tumor cells^[12].

What Conditions Does Tagraxofusp Treat?

Tagraxofusp is FDA-approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), which is a rare and aggressive type of blood cancer that affects the bone marrow and multiple organs^[4].

Additionally, clinical trials are investigating its use in several other conditions:

• Acute Myeloid Leukemia (AML) – A type of cancer that affects the blood and bone marrow, characterized by rapid growth of abnormal white blood cells^[1][2].
• Chronic Myelomonocytic Leukemia (CMML) – A type of cancer that starts in blood-forming cells of the bone marrow and invades the blood^[1].
• Myelofibrosis (MF) – A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells^[1][4].
• Various other CD123-positive hematologic malignancies – These include certain types of lymphomas and mixed phenotype acute leukemias^[12].

Researchers are particularly interested in tagraxofusp for these conditions because they typically express high levels of CD123, the protein that tagraxofusp targets^[2].

How is Tagraxofusp Administered?

Tagraxofusp is administered as an intravenous (IV) infusion, which means it’s given directly into your vein. Here are the key points about its administration:

• It’s typically given as a 15-minute infusion^[1].
• The standard dose is 12 micrograms per kilogram of body weight (μg/kg), though clinical trials may test different doses (7-16 μg/kg)^[3].
• It’s usually administered for 3-5 consecutive days in each treatment cycle^[1][2].
• Cycles are typically 21 or 28 days long, depending on the specific treatment protocol^[2][3].
• The first cycle often requires hospitalization for monitoring, while subsequent cycles may be done on an outpatient basis^[1].

Your healthcare provider will determine the appropriate dosing schedule based on your specific condition, response to treatment, and any side effects you may experience^[1].

Current Clinical Use and Research

Tagraxofusp is being studied in various clinical settings, including:

• First-line treatment for newly diagnosed patients with certain blood cancers^[3].
• Treatment for relapsed or refractory disease (cancer that has returned after treatment or doesn’t respond to treatment)^[2].
• Maintenance therapy after stem cell transplant to help prevent relapse^[1].
• Bridge to stem cell transplantation – helping patients achieve remission so they can undergo a potentially curative stem cell transplant^[3].
• Treatment for measurable residual disease (MRD) – targeting small numbers of cancer cells that remain after treatment and can lead to relapse^[11].

Clinical trials have shown promising results in certain patient populations. For example, in first-line BPDCN, tagraxofusp has shown high rates of complete response, which means all signs of cancer have disappeared with treatment^[3].

Tagraxofusp in Combination Therapies

While tagraxofusp can be used alone (as monotherapy), many clinical trials are investigating its use in combination with other cancer treatments to potentially improve outcomes. Some combination approaches being studied include:

• Tagraxofusp with venetoclax and azacitidine – This three-drug combination is being studied for AML. Venetoclax is a targeted therapy that blocks a protein called BCL-2, while azacitidine is a hypomethylating agent that can help restore normal function to certain genes^[9][11].
• Tagraxofusp with pacritinib – This combination is being studied for myelofibrosis. Pacritinib is a JAK2 and IRAK1 inhibitor that can help with symptoms and splenomegaly (enlarged spleen)^[4].
• Tagraxofusp with gemtuzumab ozogamicin – This combination is being investigated for relapsed/refractory AML. Gemtuzumab ozogamicin is another targeted therapy that delivers a toxic substance to cancer cells^[10].
• Tagraxofusp with cladribine and cytarabine – This combination is being studied for CD123-positive relapsed or refractory AML^[13].

These combination approaches aim to target cancer cells through multiple mechanisms simultaneously, potentially increasing effectiveness and reducing the chance of treatment resistance^[9].

Potential Side Effects

Like all medications, tagraxofusp can cause side effects. The most significant side effect is capillary leak syndrome, a condition in which fluid and proteins leak out of small blood vessels into surrounding tissues^[3].

Other potential side effects may include:

• Nausea and vomiting^[1]
• Fever^[1]
• Fatigue^[3]
• Decreased appetite^[3]
• Headache^[3]
• Increased liver enzymes^[1]
• Low blood counts (which can lead to increased risk of infection, bleeding, or anemia)^[3]

During clinical trials, researchers carefully monitor for these side effects and may adjust the treatment schedule or provide supportive care as needed^[1]. The safety profile of tagraxofusp, both alone and in combination with other therapies, continues to be studied^[4].

Ongoing Research and Future Applications

There are numerous ongoing clinical trials investigating tagraxofusp in various settings and combinations. Some key areas of research include:

• Dose optimization – Finding the most effective and safest dose for different patient populations^[2].
• Novel combinations – Testing tagraxofusp with other therapies to potentially enhance effectiveness^[4][9].
• Biomarker identification – Determining which patients are most likely to benefit from tagraxofusp based on specific characteristics of their cancer^[11].
• Treatment sequencing – Understanding the optimal timing of tagraxofusp in relation to other therapies^[1].
• Long-term outcomes – Assessing the durability of responses and long-term survival of patients treated with tagraxofusp^[3].

Researchers are particularly interested in the potential of tagraxofusp to target measurable residual disease (MRD), which refers to a small number of cancer cells that remain after treatment and can lead to relapse. By targeting these residual cancer cells, tagraxofusp might help prevent disease recurrence^[11].

Tagraxofusp in Pediatric Patients

Tagraxofusp is approved for pediatric patients with BPDCN, and research is ongoing to expand its use in children with other blood cancers^[12].

A Phase I study is investigating tagraxofusp, both alone and in combination with chemotherapy, in pediatric patients with relapsed or refractory CD123-expressing hematologic malignancies^[12]. This study includes children and young adults with various types of blood cancers, including AML, acute lymphoblastic leukemia (ALL), BPDCN, myelodysplastic syndromes (MDS), and certain lymphomas^[12].

The study is designed to determine the recommended phase 2 dose of tagraxofusp in pediatric patients, as well as to describe its toxicities and pharmacokinetic properties (how the drug moves through the body)^[12]. Notably, the study includes patients with Down syndrome, a population that is often excluded from clinical trials despite having a higher risk of developing certain types of leukemia^[12].

Table of Contents
– [What is Rimiducid?](#what-is-rimiducid)
– [How Rimiducid Works](#how-rimiducid-works)
– [Medical Conditions Treated with Rimiducid](#medical-conditions-treated-with-rimiducid)
– [Rimiducid in CAR-T Cell Therapy](#rimiducid-in-car-t-cell-therapy)
– [Rimiducid in Stem Cell Transplantation](#rimiducid-in-stem-cell-transplantation)
– [Safety Profile and Side Effects](#safety-profile-and-side-effects)
– [Current Research and Clinical Trials](#current-research-and-clinical-trials)
– [Future Directions](#future-directions)

What is Rimiducid?

Rimiducid (also known by its alternative name AP1903) is not a standard anti-cancer drug but rather a specialized medication designed to work as a “safety switch” in certain cellular therapies. It is administered to patients who have received genetically modified cells as part of their treatment for various conditions, particularly blood cancers and other disorders^[1].

Rimiducid serves as a critical safety mechanism in advanced cellular therapies. When patients receive genetically modified cells (such as T cells), these cells are engineered to include a self-destruct mechanism called a “safety switch” or “suicide gene.” If these modified cells cause severe side effects like Graft-versus-Host Disease (GvHD), rimiducid can be administered to activate this safety switch, causing the problematic cells to self-destruct through a process called apoptosis^[2].

This innovative approach allows doctors to have better control over cellular therapies, potentially making these treatments safer for patients.

How Rimiducid Works

Rimiducid functions through a precise molecular mechanism targeting genetically modified cells:

1. **Activation of the Safety Switch**: Rimiducid is administered intravenously, typically at doses of 0.4 mg/kg, though lower doses (0.1 mg/kg and 0.05 mg/kg) are also being investigated in some trials[3].

2. **Inducing Apoptosis**: Once administered, rimiducid binds to a special protein called inducible caspase 9 (iCasp9) that has been engineered into the modified cells. This binding causes the protein to activate, triggering a cascade of cellular events that lead to apoptosis (programmed cell death) of the modified cells[4].

3. **Targeted Cell Elimination**: This mechanism allows for selective elimination of only the genetically modified cells that contain the safety switch, while leaving other healthy cells in the body unaffected[5].

The beauty of this system is its specificity – rimiducid only affects cells that have been specifically engineered to respond to it, providing a precise way to control cellular therapies if they begin causing harmful side effects.

Medical Conditions Treated with Rimiducid

Rimiducid is not a primary treatment for any disease but rather acts as a safety component in cellular therapies for various conditions. Based on clinical trial data, these conditions include:

# Blood Cancers
– **Acute Lymphoblastic Leukemia (ALL)**: A cancer of lymphocyte blood cells that affects both children and adults[6].
– **Acute Myeloid Leukemia (AML)**: A cancer of the myeloid line of blood cells characterized by rapid growth of abnormal white blood cells[7].
– **Non-Hodgkin Lymphoma**: A group of blood cancers that includes all types of lymphoma except Hodgkin lymphomas[8].
– **Multiple Myeloma**: A cancer of plasma cells that accumulate in the bone marrow[9].
– **Myelodysplastic Syndromes (MDS)**: A group of disorders caused by poorly formed or dysfunctional blood cells[10].

# Solid Tumors
– **Metastatic Prostate Cancer**: Advanced prostate cancer that has spread to other parts of the body^[11].
– **Various Advanced Solid Tumors**: Including breast cancer, colorectal cancer, and others in experimental treatments^[12].

# Non-Malignant Conditions
– **Primary Immunodeficiency Disorders**: Inherited conditions that affect the immune system[13].
– **Hemoglobinopathies**: Genetic disorders affecting hemoglobin structure, such as sickle cell anemia[14].
– **Aplastic Anemia**: A condition where the body stops producing enough new blood cells[15].
– **Inherited Metabolic Disorders**: Conditions where the body cannot properly convert food to energy[16].
– **Systemic Lupus Erythematosus (SLE)**: An autoimmune disease in which the immune system attacks the body’s tissues and organs[17].

Rimiducid in CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a type of immunotherapy where a patient’s T cells are modified to better recognize and attack cancer cells. Rimiducid plays a crucial role in enhancing the safety of these advanced treatments.

# How CAR-T Cell Therapy Works with Rimiducid

In CAR-T cell therapy with rimiducid safety systems:

1. **T Cell Collection**: Doctors collect T cells from the patient’s blood through a process called apheresis[18].

2. **Genetic Modification**: These T cells are genetically modified in a laboratory to express:
– A chimeric antigen receptor (CAR) that targets specific proteins on cancer cells
– A safety switch gene (often the inducible caspase 9 or iCasp9 gene) that responds to rimiducid[19]

3. **Cell Expansion**: The modified T cells are grown in large numbers in the laboratory.

4. **Infusion**: The patient receives the modified CAR-T cells through an IV infusion.

5. **Monitoring and Safety Management**: If the patient develops severe side effects from the CAR-T cells (such as cytokine release syndrome or neurotoxicity), rimiducid can be administered to activate the safety switch and eliminate some or all of the CAR-T cells[20].

# Examples of CAR-T Products Using Rimiducid

Several experimental CAR-T products incorporate rimiducid-responsive safety switches, including:

– **P-BCMA-ALLO1**: Targets B-cell maturation antigen in multiple myeloma^[21].
– **P-CD19CD20-ALLO1**: Targets CD19 and CD20 proteins in B-cell malignancies^[22].
– **P-PSMA-101**: Targets prostate-specific membrane antigen in prostate cancer^[23].
– **BPX-601**: Targets PSCA (prostate stem cell antigen) in solid tumors^[24].
– **P-MUC1C-ALLO1**: Targets MUC1C in various solid tumors^[25].

Rimiducid in Stem Cell Transplantation

Stem cell transplantation is a procedure in which healthy blood-forming stem cells are used to replace damaged or diseased bone marrow. Rimiducid has been extensively studied in the context of haploidentical (partially matched) stem cell transplants.

# Role in Haploidentical Transplants

In haploidentical transplants, the donor is only a partial match to the recipient (often a parent, child, or sibling). This type of transplant carries a higher risk of Graft-versus-Host Disease (GvHD), where the donor cells attack the recipient’s body^[26].

Researchers have developed a system where:

1. **T Cell Depletion**: The donor stem cell graft is depleted of certain T cells (TCR αβ+ T cells) that can cause GvHD.

2. **Addition of Modified T Cells**: The patient receives the donor’s stem cells along with donor T cells that have been genetically modified to include a rimiducid-responsive safety switch (these modified T cells are sometimes called rivogenlecleucel or BPX-501)^[27].

3. **Safety Monitoring**: If the patient develops GvHD despite the T cell depletion, rimiducid can be administered to eliminate the modified T cells and stop the GvHD^[28].

This approach potentially allows patients to benefit from the positive effects of donor T cells (faster immune recovery, protection against infections, and anti-cancer effects) while providing a safety mechanism if GvHD occurs.

Safety Profile and Side Effects

Rimiducid itself appears to have a favorable safety profile, with most adverse events related to the underlying cellular therapy rather than the rimiducid administration.

# Common Side Effects

When rimiducid is administered, patients may experience:

– **Fever**: A temporary increase in body temperature^[29].
– **Chills**: Feeling cold and shivering despite normal or elevated body temperature^[30].
– **Fatigue**: A feeling of tiredness or exhaustion^[31].
– **Nausea**: An uncomfortable feeling in the stomach that may lead to vomiting^[32].

These effects are generally mild and temporary, often resolving within a few hours or days after administration.

# Intended Effects

It’s important to understand that when rimiducid is administered, certain effects are actually intended:

– **Reduction in modified cell numbers**: Rimiducid is designed to eliminate modified cells, so a decrease in their numbers is an expected and desired outcome[33].
– **Improvement in GvHD symptoms**: If rimiducid is given to treat GvHD, improvement in GvHD symptoms (such as skin rash, diarrhea, or liver dysfunction) indicates the medication is working properly[34].

# Special Considerations

Patients receiving rimiducid should be aware that:

– The medication is only effective against cells that have been specifically modified to include the safety switch.
– After rimiducid administration, the beneficial effects of the modified cells (such as anti-cancer activity) may be reduced or lost^[35].
– Close monitoring by healthcare providers is essential both before and after rimiducid administration.

Current Research and Clinical Trials

Rimiducid is being actively investigated in numerous clinical trials across various conditions and cellular therapy approaches.

# Key Areas of Research

Current research focuses on:

1. **Optimizing Dosing**: Studies are examining different doses of rimiducid (from 0.01 mg/kg to 0.4 mg/kg) to determine the optimal amount needed to control side effects while preserving some therapeutic benefits of the modified cells^[36].

2. **Expanding Applications**: Researchers are testing rimiducid-enabled safety switches in new types of cellular therapies, including:
– Allogeneic (donor-derived) CAR-T cells for various cancers^[37]
– Natural Killer (NK) cell therapies for solid tumors^[38]
– T cell therapies for autoimmune diseases like lupus^[39]

3. **Long-term Safety**: Studies are following patients for up to 15 years after receiving modified cells with rimiducid-responsive safety switches to monitor for any long-term effects^[40].

# Notable Clinical Trials

Some significant ongoing clinical trials involving rimiducid include:

– **NCT06014762**: Investigating P-CD19CD20-ALLO1 allogeneic CAR-T cells with rimiducid safety switch for B-cell malignancies[41].
– **NCT04960579**: Studying P-BCMA-ALLO1 allogeneic CAR-T cells with rimiducid safety switch for multiple myeloma[42].
– **NCT05239143**: Examining P-MUC1C-ALLO1 CAR-T cells with rimiducid safety switch for advanced solid tumors[43].
– **NCT06984341**: Evaluating P-CD19CD20-ALLO1 for treatment-refractory systemic lupus erythematosus[44].

Future Directions

The field of cellular therapy with built-in safety mechanisms is rapidly evolving, with rimiducid playing a central role in these innovations.

# Emerging Applications

Researchers are exploring several promising new applications for rimiducid-enabled safety systems:

1. **Autoimmune Disease Treatment**: Using modified T cells with safety switches to target and reset the immune system in diseases like lupus, multiple sclerosis, and rheumatoid arthritis[45].

2. **Solid Tumor Therapies**: Developing more effective CAR-T and CAR-NK cell therapies for solid tumors with enhanced safety profiles through rimiducid-responsive switches[46].

3. **Combination Approaches**: Integrating rimiducid-enabled safety mechanisms with other emerging technologies, such as:
– Gene editing (CRISPR/Cas9) to create more precise cell modifications
– Controllable activation systems to turn cellular therapies “on” and “off” as needed[47]

# Patient Impact

As research progresses, patients may benefit from:

– **Wider Availability**: More centers offering cellular therapies with built-in safety mechanisms
– **Expanded Eligibility**: More patients qualifying for these therapies due to improved safety profiles
– **Outpatient Administration**: Some therapies potentially moving from inpatient to outpatient settings as safety improves^[48]

### Challenges to Address

Despite promising advances, several challenges remain:

– **Cost**: Cellular therapies with advanced safety mechanisms are expensive to develop and administer
– **Manufacturing Complexity**: Adding safety switches increases the complexity of producing modified cells
– **Balancing Safety and Efficacy**: Finding the optimal approach to preserve therapeutic benefits while providing adequate safety controls^[49]

Rimiducid represents an important advancement in making cellular therapies safer and more controllable, potentially expanding their application to more patients and conditions in the future.

Table of Contents

• What is RADIUM RA 223 DICHLORIDE?
• How does it work?
• What conditions does it treat?
• How is it administered?
• Combination therapy
• Effectiveness
• Side effects
• Ongoing research

What is RADIUM RA 223 DICHLORIDE?

RADIUM RA 223 DICHLORIDE is a medication used to treat certain types of prostate cancer. It’s also known by several other names, including Xofigo, Alpharadin, and BAY 88-8223^[1]. This drug is specifically designed to target cancer that has spread to the bones, a condition known as bone metastases^[2].

How does it work?

RADIUM RA 223 DICHLORIDE is what’s called a radiopharmaceutical drug. This means it combines a radioactive substance (radium-223) with a pharmaceutical. When injected into the body, it targets areas where cancer has spread to the bones. The radium-223 then releases small amounts of radiation, which can damage and kill cancer cells^[10].

Interestingly, this medication works differently from many other cancer treatments. It specifically targets areas of increased bone turnover, which is common in bone metastases. This targeted approach helps to minimize damage to healthy tissues^[1].

What conditions does it treat?

RADIUM RA 223 DICHLORIDE is primarily used to treat a specific type of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones. Let’s break down what this means:

• Metastatic: The cancer has spread from the prostate to other parts of the body, particularly the bones.
• Castration-resistant: The cancer continues to grow even when the levels of male hormones (like testosterone) are reduced to very low levels.

This medication is typically used when the cancer has spread to the bones but not to other organs (like the liver or lungs)^[3][5].

How is it administered?

RADIUM RA 223 DICHLORIDE is given as an intravenous (IV) injection. This means it’s injected directly into a vein. The typical treatment schedule is:

• One injection every 4 weeks
• A total of 6 injections over 24 weeks (about 6 months)

The dose is usually calculated based on the patient’s body weight. A common dose is 55 kilobecquerel (kBq) per kilogram of body weight^[2][3].

Combination therapy

RADIUM RA 223 DICHLORIDE is sometimes used in combination with other prostate cancer treatments. Some studies have looked at using it together with medications like:

• Enzalutamide: A hormone therapy that blocks the effects of testosterone^[2].
• Abiraterone acetate: Another hormone therapy that works by stopping the body from producing testosterone^[8].
• Paclitaxel: A chemotherapy drug^[4].

However, it’s important to note that some combinations may increase the risk of side effects. Your doctor will carefully consider the best treatment plan for your specific situation^[6].

Effectiveness

Studies have shown that RADIUM RA 223 DICHLORIDE can be effective in treating mCRPC with bone metastases. It may help to:

• Reduce bone pain
• Slow the progress of the disease
• Improve overall survival (help patients live longer)

Researchers are still studying how effective this treatment is when used alone or in combination with other therapies^[10].

Side effects

Like all medications, RADIUM RA 223 DICHLORIDE can cause side effects. Some of the most common include:

• Myelosuppression: This is a decrease in bone marrow activity that can lead to lower blood cell counts. It may cause anemia (low red blood cells), neutropenia (low white blood cells), or thrombocytopenia (low platelets)^[4].
• Nausea and vomiting
• Diarrhea
• Fatigue

Your healthcare team will monitor you closely for these and other potential side effects during treatment^[10].

Ongoing research

Researchers continue to study RADIUM RA 223 DICHLORIDE to better understand its effects and explore new ways to use it. Some areas of ongoing research include:

• Using it earlier in the course of prostate cancer treatment^[3]
• Combining it with other treatments to potentially improve effectiveness^[2][4]
• Studying its effects on quality of life and pain relief^[10]
• Investigating how genetic factors might influence how well the treatment works^[1]

These ongoing studies aim to help doctors use RADIUM RA 223 DICHLORIDE more effectively and improve outcomes for patients with prostate cancer that has spread to the bones.

Table of Contents

• What is Ranitidine Hydrochloride?
• Medical Uses
• How is Ranitidine Administered?
• Effectiveness
• Side Effects and Safety
• Comparisons with Other Medications
• Ongoing Research

What is Ranitidine Hydrochloride?

Ranitidine Hydrochloride, commonly known by its brand name Zantac, is a medication that belongs to a class of drugs called histamine-2 (H2) receptor antagonists^[1]. These drugs work by reducing the amount of acid produced in the stomach. Ranitidine is available in various forms, including tablets, oral solutions, and intravenous (IV) formulations^[3].

Medical Uses

Ranitidine Hydrochloride is used to treat a variety of conditions related to excess stomach acid. These include:

• Dyspepsia: This is a general term for indigestion, which can include symptoms like upper abdominal pain, bloating, and nausea^[3].
• Gastric Ulcers: Ranitidine can be used to heal ulcers in the stomach, particularly those associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs)^[6].
• Stress Ulcer Prophylaxis: In critically ill patients, ranitidine may be used to prevent stress-related ulcers from forming in the stomach^[11].
• Gastroesophageal Reflux Disease (GERD): While not explicitly mentioned in the trials, ranitidine is commonly used to treat GERD symptoms.

How is Ranitidine Administered?

Ranitidine can be administered in several ways, depending on the condition being treated and the patient’s needs:

• Oral tablets: These are available in various strengths, including 150 mg and 300 mg^[4].
• Intravenous (IV) injection: In hospital settings, ranitidine may be given as an IV infusion, typically in doses of 50 mg^[3].
• Oral Disintegrating Tablets (ODT): These are tablets that dissolve in the mouth without needing water^[1].

The dosage and frequency of administration can vary depending on the condition being treated. For example, in some studies, ranitidine was given as 150 mg twice daily^[6].

Effectiveness

Ranitidine has been shown to be effective in various clinical scenarios:

• Healing of gastric ulcers: Studies have compared ranitidine to other medications like esomeprazole for healing NSAID-associated gastric ulcers^[6].
• Relief of dyspeptic pain: Ranitidine has been studied for its ability to reduce pain associated with dyspepsia in emergency department settings^[3].
• Increasing gastric pH: In critically ill patients, ranitidine has been shown to increase gastric pH, which can help prevent stress ulcers^[11].

Side Effects and Safety

Ranitidine is generally considered safe and well-tolerated. However, like all medications, it can have side effects. Common side effects may include headache, dizziness, and gastrointestinal disturbances. In clinical trials, researchers often monitor for adverse events to ensure the safety of the medication^[6].

It’s important to note that in recent years, there have been concerns about potential contamination of some ranitidine products with a substance called N-nitrosodimethylamine (NDMA). This led to recalls in some countries. Patients should always consult with their healthcare provider about the most current safety information.

Comparisons with Other Medications

Several studies have compared ranitidine to other medications used for similar purposes:

• Esomeprazole: This is a proton pump inhibitor (PPI) that has been compared to ranitidine for healing gastric ulcers and treating dyspepsia^[6][3].
• Pantoprazole: Another PPI that has been compared to ranitidine for treating dyspepsia in emergency department settings^[10].

These comparisons help healthcare providers determine the most appropriate treatment for each patient’s specific condition.

Ongoing Research

Research on ranitidine continues to explore its potential benefits beyond its traditional uses:

• HIV research: Some studies have investigated whether ranitidine can enhance the effectiveness of other medications in HIV treatment^[5].
• Cancer research: Preliminary studies have looked at whether ranitidine might have effects on the immune system that could be beneficial in cancer treatment^[7]. However, it’s important to note that this is still in the research phase and ranitidine is not approved as a cancer treatment.

These ongoing studies highlight the continued interest in understanding the full potential of ranitidine in various medical contexts.